Classic hereditary hemochromatosis is an autosomal recessive disorder characterized by iron overload and sequence variants in the HFE gene. The HFE gene is located at 6p21.3 and contains 2 common single nucleotide polymorphisms (SNPs) C282Y and H63D, which are routinely tested for in the molecular diagnostics laboratory. In this study, we used DNA samples from 59 patients in which clinicians wanted to confirm or rule-out hereditary hemochromatosis that had been previously tested for the HFE SNPs using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay and the ABI 7700 real time PCR assay with a MGB Eclipse ASR Probe system. The new assay used TAQman SNP Genotyping Assays, which were performed on the ABI 7500 FAST real time PCR platform. Allelic discrimination was determined during a postamplification plate read. Of the 59 samples genotyped, 7 were homozygous for C282Y, 6 were heterozygous for C282Y, 9 were homozygous for H63D, 10 were heterozygous for H63D, 6 were compound heterozygotes, and 20 were wild type. With the exception of one sample that was indeterminate by the TAQman SNP Genotyping Assay, all others showed 100% concordance between the 3 assays. The one indeterminate sample was heterozygous for C282Y by the PCR-RFLP and ABI 7700 real time PCR assays, but there was an insufficient quantity of DNA to perform the TAQman SNP Genotyping Assay. Our study suggests that the ABI 7500 FAST TAQman SNP Genotyping Assay is comparable with the PCR-RFLP and ABI 7700 real time PCR methods in detecting and characterizing these 2 HFE SNPs. Improved software and thermocycling capabilities have resulted in a very robust TAQman assay with the advantage of a much improved turnaround-time and throughput.
C lassic hereditary hemochromatosis is an autosomal recessive disorder involving mutations in the HFE gene that leads to the increased intestinal absorption and subsequent deposition of iron in tissues including the liver, pancreas, and heart. 1 It is the most common autosomal recessive gene defect in the white population, affecting about 1 in 250 people of northern European ancestry. 2 Early detection is important because early treatment can have an impact on patients' morbidity and mortality. The HFE gene, located at 6p21.3, contains 2 common single nucleotide polymorphisms (SNPs) that are routinely tested for in the molecular diagnostics laboratory. Most commonly, patients are homozygous for a missense cysteine-to-tyrosine SNP mutation (C282Y) on exon 4 at position 282 [HFE NM_000410.3:c.845G> A(p.Cys282Tyr)]; the other SNP (H63D), usually found in compound heterozygosity with the C282Y mutation, is a histidine-to-aspartic acid mutation on exon 2 at position 63 [HFE NM_000410.3:c.187C>G (p.His63Asp)]. 3, 4 This study describes the detection of these 2 SNPs using the ABI 7500 FAST real time polymerase chain reaction (PCR) system in 59 patients in which clinicians wanted to confirm or rule-out hereditary hemochromatosis. A third SNP, S65C, occurs in very low frequency but has been shown to have a slight effect on iron indices, especially in conjunction with C282Y and H63D mutations. No convincing data link the S65C SNP to hereditary hemochromatosis and therefore, testing patients with increased serum iron indices for S65C is insufficient to confirm the presence of hereditary hemochromatosis. 1 
MATERIALS AND METHODS

Samples
In this study, we used DNA samples from 59 patients who had been previously tested for the HFE C282Y and H63D SNPs using a PCR-restriction fragment length polymorphism (PCR-RFLP) assay and the ABI 7700 real time PCR assay with a MGB Eclipse ASR Probe system. Clinicians desired to confirm or rule-out hereditary hemochromatosis in these patients (on the basis of iron indices, family history, and/or clinical symptoms). DNA from all samples was isolated from whole blood using the PureGene Kit (Gentra, Inc, Minneapolis, MN). 
PCR-RFLP
The PCR-RFLP assay uses restriction enzyme digests to detect the difference between normal and SNP sequences for each mutation. For each patient sample, relevant portions of exons 2 (H63D locus) and 4 (C282Y locus) were amplified and restriction digested with NIaIII and RsaI, respectively, according to the method of Feder et al. 3 The H63D mutation destroys a NIaIII site and the C282Y mutation creates a RsaI site. The digested products were electrophoresed on a 3% 3:1 Agarose gel (Amresco, Solon, OH) and visualized using ethidium bromide ( Fig. 1 ).
ABI 7700 Real Time PCR
The ABI 7700 real time PCR assay with a MGB Eclipse ASR Probe system (Epoch Biosciences, Bothell, WA) was performed in transparent 96-well plates (PerkinElmer, Boston, MA) as follows. For each locus, approximately 10 to 20 ng of DNA was amplified in a 25 mL reaction containing 1 Â PCR Buffer, 1 Â primer mix, 1 Â probe mix and 2 units Hotstart Taq (Sigma, St Louis, MO). Probes and primers for normal and SNP sequences were combined into a single reaction volume for each HFE mutation. Cycling conditions were as follows: 1 cycle of 501C, 2 min/951C, 2 minutes; 45 cycles of 951C, 5 s/561C, 20 s/761C, 20 seconds; 1 melt cycle of 951C, 15 s/401C, 15 seconds; a 5-minute ramp-up to 801C and a 15-second hold at 801C. Data were collected during the thermocycling at the annealing step only and during the 5 minutes ramp-up to 801C in the melt cycle. Multicomponent data were exported from the ABI 7700 as a .txt file. These data were then imported into the Eclipse Melt Macro supplied by EPOCH (Nanogen, Inc., San Diego, CA). The program plots the melt curve data and automatically calculates the identity of the alleles based on the input primer and probe data (Fig. 2) . Table 1 shows the primers and probes used for the ABI 7700. 
ABI 7500 FAST Real Time PCR
The new TAQman assay on the ABI 7500 used 2 predesigned ABI Assays-on-demand (www.appliedbiosystems.com) containing primers and fluorescently labeled (FAM and VIC) MGB probes (20 Â ) for detection of the SNPs from the National Cancer Institute's SNP500 database (http://snp500cancer.nci.nih.gov/home.cfm). Assays were run with the predesigned primer and probe SNP Genotyping Assays: C_1085595 (C282Y) and C_1085600 (H63D) using ABI 2 Â fast universal master mix, 10 to 20 ng of genomic DNA in a total reaction volume of 10 mL using the default fast cycling conditions in transparent 96-well plates. The completion time is about 40 minutes. A postamplification plate read was used for allelic discrimination using the SDS software supplied with the instrument (Fig. 3 ).
RESULTS
Of 59 samples, 7 were homozygous for C282Y, 6 were heterozygous for C282Y, 9 were homozygous for H63D, 10 were heterozygous for H63D, 6 were compound heterozygotes, and 20 were wild type by all 3 assays ( Table 2) . One sample was heterozygous for C282Y by the PCR-RFLP and ABI 7700 real time PCR assays, but there was an insufficient quantity of DNA to perform the TAQman SNP Genotyping Assay.
DISCUSSION
Classic hemochromatosis (HFE gene mutations) is one of at least 4 main types of hereditary hemochromatosis involving a number of genes and proteins involved in iron regulation within the body. Symptoms of hemochromatosis in the classic form are most commonly seen in C282Y homozygotes and less frequently in C282Y/H63D compound heterozygotes. Recent surveys involving HFE genotyping of general populations found that most C282Y homozygotes had incomplete penetrance with no clinical symptoms. 5 This study raises the question of the value and cost-effectiveness of screening the general population. However, the ongoing Hemochromatosis and Iron Overload Screening (HEIRS) Study found that within the white participants 64% of men with adjusted transferrin saturation (TS)Z50% had a HFE polymorphism and 63% of women with adjusted TS valueZ45% had a HFE polymorphism. They also showed that the positive predictive value for prediction of HFE gene polymorphism increased as the adjusted TS threshold increased. 6 These results from the HEIRS study will be important in defining the screening guidelines in patients with increased iron indices for use in clinical practice.
The recently identified peptide hepcidin is believed to be the regulator that controls iron absorption and release by inducing the internalization and degradation of ferroportin, a major transmembrane iron exporter protein of macrophages and enterocytes. The function of the HFE gene in iron metabolism is now characterized by the ''hepcidin model'' hypothesis. Hepcidin is synthesized in the liver. Data suggest that HFE along with transferrin receptors 1 and 2 play a role in the iron-sensing pathway of hepatocytes, which subsequently regulates hepcidin synthesis. It is still unclear how HFE acts in this ironsensing pathway, but hepcidin urine concentrations negatively correlate with the severity of hemochromatosis. 1 Eventually, hepcidin urine and plasma assays will probably play a role in screening patients for iron overload diseases; however, these assays are not yet widely available. Currently, when iron overload is suspected (hyperferritinemia and/or increased TS are found) and acquired causes have been excluded, diagnosis of hereditary causes via molecular pathology techniques is considered.
In our study, patients were initially screened because clinicians wanted to confirm or rule-out classic hereditary hemochromatosis. With the exception of one sample that was indeterminate by the TAQman SNP Genotyping Assay, all others showed 100% concordance between assays. Our study suggests that the ABI 7500 FAST TAQman SNP Genotyping Assay is comparable with the PCR-RFLP and ABI 7700 real time PCR methods in detecting and characterizing these 2 HFE SNPs. Improved software and thermocycling capabilities have resulted in a very robust TAQman assay that has decreased analytical turn around times as compared with the ABI 7700 and gel-based PCR-RFLP assays. In addition, the 96-well plate format allows for a higher throughput than the gel-based assay. Wild type 20 20 20 Total* 58* 59 59 *One indeterminate sample on the TAQman SNP Genotyping Assay (due to insufficient quantity of DNA), which was heterozygous for C282Y by the PCR-RFLP and ABI 7700 real time PCR assays.
